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Mutations in the human FBN1 gene are known to be associated with the Marfan syndrome, an autosomal dominant inher-
ited multi-systemic connective tissue disorder. However, in the absence of solid genotype–phenotype correlations, the identiﬁ-
cation of an FBN1 mutation has only little prognostic value. We propose a bioinformatics framework for the mutated
FBN1 gene which comprises the collection, management, and analysis of mutation data identiﬁed by molecular genetic analysis
(DHPLC) and data of the clinical phenotype. To query our database at diﬀerent levels of information, a relational data model,
describing mutational events at the cDNA and protein levels, and the diseases phenotypic expression from two alternative
views, was implemented. For database similarity requests, a query model which uses a distance measure based on log-likelihood
weights for each clinical manifestation, was introduced. A data mining strategy for discovering diagnostic markers, classiﬁcation
and clustering of phenotypic expressions was provided which enabled us to conﬁrm some known and to identify some new
genotype–phenotype correlations.
 2005 Elsevier Inc. All rights reserved.
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FBN1 (OMIM #134797) is the gene known to be
associated with the Marfan syndrome (MFS, OMIM
#154700), an autosomal dominant inherited multi-sys-
temic connective tissue disorder with prominent clinical
manifestations in the cardiovascular, musculoskeletal,
and ocular systems (OMIM: www.ncbi.nlm.nih.gov/en-
trez/query.fcgi?db=OMIM). Its prevalence is 1/5000.
In about 70% of MFS patients, mutations in the1532-0464/$ - see front matter  2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2005.06.001
* Corresponding author. Fax: +43 50 8648 673827.
E-mail address: christian.baumgartner@umit.at (C. Baumgartner).FBN1 gene could be detected [1]. The following catego-
ries of FBN1 mutations have been described: nucleotide
substitutions (missense, nonsense, silent, and splicing
mutations), insertions, deletions, indels, duplications,
and complex rearrangements, some of which cause pre-
mature termination and exon skipping, respectively
[2–4].
The diagnosis of MFS is dependent on a catalogue of
international diagnostic criteria summarized in the Gent
nosology [5]. The major source of morbidity and early
death in MFS relates to the cardiovascular system.
Weakness of the aortic wall can lead to aortic dissection
or rupture [6]. However, before life threatening compli-
cations occur, alterations of aortic elastic properties can
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aortic elasticity during care follow-up [7–10].
Molecular genetic testing like mutation scanning or
cDNA sequence analysis has been proposed as an ad-
junct to the clinical diagnosis of the MFS [5,11,12].
However, many mutations of FBN1 cause phenotypic
expressions that are distinct from MFS, which rely on
the age-related and pleiotropic nature of the disease
[13]. Furthermore, only few genotype–phenotype corre-
lations have been found in MFS [1,13–17]. In the ab-
sence of solid genotype–phenotype correlations, the
identiﬁcation of an FBN1 mutation has only little prog-
nostic value or consequence for the patients diagnostic
and therapeutic management.
In this work, we developed a bioinformatics frame-
work to support genotype–phenotype correlations
using a suite of statistical methods, algorithms and
database applications: Core component is an FBN1
information system which collects, manages and ana-
lyzes genetic information as gained from molecular
genetic testing and clinical data according to a stan-
dardized catalogue of diagnostic criteria. To query
the database (DB) at diﬀerent levels of genetic and phe-
notypic information, a relational data model was devel-
oped which models mutational events at the cDNA
and protein levels, and MFS phenotypic expression
from two alternative views. A query model was intro-
duced which uses a distance measure based on log-like-
lihood weights for each clinical manifestation to query
the DB for mutations of related phenotypic expres-
sions. A straightforward data mining strategy for the
identiﬁcation of diagnostic markers, classiﬁcation and
cluster analysis of phenotypic expressions was provided
to perform genotype–phenotype investigations. Initial
experiments conﬁrmed some known correlations and
identiﬁed some novel ones when using the proposed
framework.2. Methods
2.1. Genotyping and phenotyping
2.1.1. FBN1 gene and ﬁbrillin-1 protein
The FBN1 gene, located on chromosome 15q21.1, is
about 236 kb in size and contains 65 exons. The gene
is transcribed in a 9.7 kb mRNA which encodes a
2871 amino acids large ﬁbrillin-1 glycoprotein
(320 kDa). Fibrillin-1 is ubiquitously distributed in con-
nective tissue and mainly made up of calcium-binding
epidermal growth factor (cb-EGF)-like, EGF-like, and
cysteine rich domains interacting with many extracellu-
lar matrix components. For general information on
the FBN1 gene see: www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=gene, www.dsi.univ-paris5.fr/genatlas or
www.umd.be:2030/Protein.html.2.1.2. Mutation analysis of the FBN1 gene
Denaturing high-performance liquid chromatogra-
phy (DHPLC) of all 65 FBN1 exons is available on a
clinical basis. Genomic DNA samples were ampliﬁed
exon by exon by means of a polymerase chain reaction
(PCR) using intron-speciﬁc primers. Quality and quanti-
ty of PCR products were determined on 1.5% agarose
gel by standard procedures. Amplicons were analyzed
by DHPLC followed by direct sequencing of amplicons
with abnormal elution proﬁles. The mutations found
were veriﬁed by repeated sequencing on newly ampliﬁed
PCR products. In the case of splice site mutations and
when no mutation was detected by DHPLC, FBN1 tran-
scripts were analyzed by the reverse transcription (RT)-
PCR of RNA templates isolated from ﬁbroblasts. RT-
PCR ampliﬁcations and sequencing of transcripts were
also performed by standard procedures [18].
2.1.3. The clinical phenotype
Classic or suspected MFS is a clinical diagnosis based
on family history and the observation of characteristic
manifestations in multiple organ systems [5]. The man-
agement of data collection requires the coordinated in-
put of a multidisciplinary team of specialists including
cardiologists, ophthalmologists, orthopedists, and
geneticists. Within our Innsbruck/Zurich FBN1-net-
work, anonymized clinical, and genetic data (mutation
scanning is performed by the Zurich group, University
Childrens Hospital Zurich, Switzerland) are brought
together at the Innsbruck Marfan Clinical Center, Clin-
ical Division of Pediatric Cardiology, Innsbruck Medi-
cal University, ready for entering into the database.
2.2. The database
For our experiments, genetic and phenotypic data has
been collected from diﬀerent sources. The data were
anonymously provided by the University Childrens
Hospital of Zurich, Switzerland and Innsbruck Medical
University, Austria [9], and extended by data recently
published [17,19–22].
Our current research DB contains 163 entries with 127
diﬀerent mutations (mean patients age 24.3 ± 15.4
years). The diﬀerent numbers of entries and mutations
arise from entries of 22 families (between two and six fam-
ily members) carrying the same mutation. One hundred
and nineteen entries are substitutions (Sub), 44 are dis-
tributed amongst deletions (Del), insertions (Ins), dupli-
cations (Dup), and indel mutations (Indel). The group
of substitutions can be split into 78 missense (Mis), 27
nonsense (Stop), and 14 splice site mutations (Splice).
Out of the pool of non-substitutions (Del, Ins, Dup, and
Indel) 31 entries are deletions causing frameshift (FS)
and premature termination codon (PTC).
We investigated 14 Gent criteria which were consis-
tently described in the publications presenting clinical
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system: 2. dilation of ascending aorta (AADIL), 3. dis-
section of ascending aorta (AADIS), 4. mitral valve pro-
lapse (MVP); skeletal system: 5. pectus carinatum (PC),
6. pectus excavatum requiring surgery (PES), 7. arm
span ratio (ASR), 8. wrist or thumb sign (WTS), 9. sco-
liosis (SC), 10. moderate pectus excavatum (PE), 11.
joint hypermobility (JH), 12. highly arched palate with
crowding of teeth (HAP); skin system: 13. striae atrophi-
cae (SA) and 14. herniae (HE). For a more detailed
description see Fig. 1B.
2.3. FBN1 information system
The information system, which is embedded in a
J2EE three tier architecture consisting of client, applica-
tion and data tier, provides cross-DBMS (database
management system) connectivity to a relational DBMS
using a modern server environment and JDBC technol-
ogy. A genotype–phenotype data model was designedFig. 1. Genotype–phenotype data model depicted as simpliﬁed UML class
modelled as 0..1 relationships. (A) Genotype data model (top): type of mutati
sub-types, and a general genotype description class are modeled. (B) Phenoty
of phenotypic information (level of system involvement and number of acc
major and minor criteria). The model is supplemented by a general phenotyand implemented to query the database at diﬀerent lev-
els of genetic and phenotypic information (see next sec-
tion). Modules for data collection, administration, and
analysis are provided as web-based services, which are
still under construction.
2.4. Genotype–phenotype data model
An international nomenclature system has been sug-
gested for the description of mutations and polymor-
phisms in DNA and protein sequences [23]. Based on
these recommendations, we designed a genotype data
model which describes sequence variations at both
cDNA and protein levels, systematically. Fig. 1A depicts
the genotype data model represented by a simpliﬁed
UML class diagram. The top compartment contains
the name of the class (= DB relation), the bottom com-
partment the list of attributes declared as SQL data
types. Associations between relations are modeled by
0.1 relationships.diagram. Attributes are declared as SQL data types. Associations are
ons at the cDNA level and their consequences at the protein level, their
pe data model (bottom): each organ system is represented by two levels
umulated symptoms, and level of single manifestations separated into
pe description class.
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vel wasmodeled by introducing class attributes according
to the international mutation nomenclature. To deﬁne
mutations, diﬀerent sub-types of nucleotide changes were
considered. The consequence of mutations at the protein
level are described and modeled in a similar way. The
genotype general description class represents the combi-
nation of mutation types at the DNA level and their con-
sequence at the protein level, the aﬀected exons/introns
and protein domains. For representation issues three dif-
ferent mutations are exempliﬁed in Table 1.
The phenotype data model was designed according
to the multi-systemic picture of the disease (GentTable 1
Three examples of FBN1 mutations described by the genotype data model
Sub/Mis
Nucleotide changes—DNA level
Name 3410G > C
wt codon CGC
Mutant codon CCC
Nucleotide position 3410
Event G > C
Exon coding region aﬀected 1
Intron 5 0 part aﬀected 0
Intron 3 0 part aﬀected 0
Gene ﬂanking or UTR region aﬀected 0
Substitution—DNA
Transversion 1
Transition 0
Deletion—DNA
Single nucleotide deletion
Several nucleotide deletion
Deleted unit
Deleted length
Amino acid changes—protein level
Name R1137P
Codon position 1137
wt AA R
mutant AA P
Substitution—Prot
Silent change 0
Missense change 1
Nonsense change 0
Translation termination site 0
Translation initiation site 0
Frameshift
AA changed into Stop
Stop position
Length of new reading frame
Genotype general description
Type and consequence Sub/Mis
Aﬀected exon/intron e27
Aﬀected domain cb-EGF 17
Nucleotide changes at the cDNA level, amino acid (AA) changes at the prote
are exempliﬁed for a substitution/missense mutation (Sub/Mis), a substitution
Fs). Attribute values are given in SQL data types. The Deletion-Prot class is
one AA.nosology). Fig. 1B depicts the UML class diagram
of the clinical phenotype in more detail: Each aﬀected
organ system, i.e., the skeletal, cardiovascular (CVS),
ocular, pulmonary, skin and integument, and dura
system, was modeled from a more general view to
emphasize the system involvement and the accumulat-
ed number of diagnosed criteria. To be more speciﬁc,
each organ system was further separated into sub-sys-
tems which contain the single manifestations. A gen-
eral patient information class provides additional
information according to the patients ethnics, sex,
age, MFS type (e.g., classical, suspected), and family
history.Sub/Stop Del/Fs
6339T > G 1206del1
TAT CCT
TAG CCC
6339 1206
T > G FS+PTC
1 1
0 0
0 0
0 0
1
0
1
0
T
1
Y2113X P404HfsX44
2113 404
Y P
X H
0
0
1
0
0
V
447
44
Sub/Stop Del/Fs
e51 e10
LTBP 6 Pro-rich
in level speciﬁed by their subtypes, and a general genotype description
/nonsense mutation (Sub/Stop) and a deletion causing FS + PTC (Del/
not exempliﬁed because it is only relevant for deleted units of at least
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We introduce a query model based on log-likelihood
weights for each of the Gent criteria to query the DB for
mutations of related phenotypes. In the following the
log-likelihood weights are deﬁned as phenotype scores.
2.5.1. Phenotype score calculation
Let DB be a genotype–phenotype database organized
in the form of a set of tuples
T ¼ fðcj; oÞjcj 2 C; o 2 DB && o ¼ ½0; 1g; ð1Þ
where cj is a speciﬁed mutation class and o is the set of
clinical manifestations (0/1). The symbol 2 means ‘‘be-
long to,’’ && is ‘‘and.’’ It is important to note that
mutation classes can be speciﬁed at diﬀerent levels of
mutational information: (i) at the level of mutation type
(DNA level), e.g., a substitution, (ii) at the level of muta-
tion type and consequence (DNA and protein level),
e.g., substitution/missense, or (iii) at the level of muta-
tion type and consequence, and location of mutational
event(s) in the gene or the aﬀected protein domain(s),
e.g., substitution/missense/exons 3–5 or EGF domain.
However, if enough tuples of an explicit mutation are
available, a score set at this highest level of mutational
information is generable. We propose at least 25 tuples
per class/type of mutations to generate representative
score sets.
The entropy of a phenotype probability distribution
P = (p1, . . . ,pN) is deﬁned as
HðP Þ ¼ Eðlog2PÞ ¼ 
XN
i¼1
pilog2pi; ð2Þ
where pj is the frequency (probability) of a symptom
within the class cj. H(P) is the entropy of the Gent phe-
notype with respect to (w.r.t.) a class cj in bit. N is the
total number of considered symptoms.
The relative entropy of two probability distributions
P and Q is computed as
HðP ;QÞ ¼ 
XN
i¼1
pilog2
pi
qi
; ð3Þ
where pi is again the frequency of a symptom within
class cj while qi is deﬁned as the frequency of the symp-
tom in DB, excluding all tuples of class cj.
A score value si of a single symptom w.r.t. class cj is
thus given as
si ¼ k  pilog2
pi
qi
; ð4Þ
where k is a scaling factor (we set k = 100). The score
value si can be interpreted as a measure of the distance
between pi and qi. If pi equals qi then si is 0. If pi is 0,
si is undeﬁned. To consider a symptom that is not pres-
ent in class cj through a corresponding score value, si canbe set to 0 under the assumption that piﬁ 0. Conse-
quently, positive si values indicate the symptoms fre-
quencies w.r.t. class ci above qi (frequencies in
DB  ci), negative values below them.
A matrix M of score sets can be generated, where
cj 2 C represent speciﬁed mutation classes at the same
level of mutational information, e.g., Sub/Mis, Sub/
Stop, Del/Fs, Ins/Fs, etc:
M ¼ fðcj; sÞjcj 2 C; s 2 S && s 2 Rg; ð5Þ
where s is the set of score values of a clinical phenotype
w.r.t. mutation class cj and S is the collectivity of score
sets in M. The symbol R represents the set of all real
numbers.
To assess phenotypic similarity/dissimilarity between
a speciﬁed mutation class cj 2 M and a requested MFS
phenotype we calculate the parameter sc, a measure
for the information content of a given score set. It is
deﬁned:
sc ¼
XN
i¼1
jsij. ð6Þ
The larger sc, the smaller the phenotypic similarity be-
tween a mutation class cj and the requested phenotype.
2.5.2. Similarity requests on speciﬁed mutation classes
To assign a query phenotype O = {o|(o1, . . . ,oN),
o 2 (0,1)} of unknown mutation to a speciﬁed mutation
class cj 2M, we present a matching paradigm that oper-
ates on matrix M by processing similarity requests for
each class cj 2M. Two steps must be processed for this
task:
1. Balancing of the score matrix M w.r.t. all speciﬁed
mutation classes c 2 M. The absolute score values
sc of classes c 2 M can signiﬁcantly diﬀer in size
which can lead to a preferred assignment of the
query tuple O to that class cj which is represented
by the highest measure sc within M. Therefore,
each score set s 2 S has to be corrected to the
mean absolute score sc, which is calculated as the
mean value of all sc 2 M, to balance matrix M.
Therefore, M* is the sc-balanced matrix of M with
s* 2M*.
2. Assignment of the query phenotype O weighted by
the balanced score sets s* 2M* to a mutation class
cj 2M*. The decision rule is deﬁned as follows:
C¼ argmax
c2M
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
i¼1
ðsi oiÞ2
vuut
0
@
1
Afor oi ¼ 1 if symptom is present;
0 if symptom is absent.

ð7Þ
Here, the query model built on a square distance mea-
sure assigns the MFS query phenotype O to that muta-
tion class cj 2 M*, whose distance is maximal.
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For searching mutations of related phenotypic
expression in DB, a similarity request at the level of
explicit mutations can be processed if score sets of single
mutations can be generated. We know from the clinical
situation that more than 20–25 subjects per mutation are
not available because of the multiplicity of mutations.
We therefore propose at least 5–10 tuples per mutation
for the scoring task. An explicit mutation ms, of which
a score set s can be generated, can formally be written as
ms ¼ fsjs 2 S && s 2 Rg. ð8Þ
Let DB be a genotype–phenotype database at the level
of single mutations given in the form of a set of tuples
T ¼ fðmj; oÞjmj 2 MU ; o 2 DB && o 2 ½0; 1g; ð9Þ
wheremj is an explicit mutation and o is the set of clinical
manifestations. MU is the collectivity of all diﬀerent
mutations represented in DB. For aDB request the query
model of mutation ms uses the following similarity
measure:
s^m ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXN
i¼1
ðsi  oiÞ2
vuut . ð10Þ
Here, s 2 S represents the score set of mutation ms as de-
ﬁned in Eq. (8) (cf. Table 3, M5). The best ranked hits T
according to maximal value of sˆm are returned as the que-
ry result.
2.6. Data mining strategy
We propose a straightforward data mining procedure
to support feature selection, classiﬁcation, and cluster
analysis suitable for correlating mutational and clinical
information.
2.6.1. Feature selection and probabilistic models
Feature selection is an important task for genotype–
phenotype correlation aiming at the identiﬁcation of
clinical key manifestations (‘‘diagnostic markers’’) from
the collection of given diagnostic criteria. In particular,
classiﬁcation accuracy of machine learning methods of-
ten degrades if the number of features in data is large
resulting in many of them becoming irrelevant for clas-
siﬁcation [24,25].
For our framework we propose the so-called wrapper
approach with logistic regression analysis (LRA) as the
learning method [26–28]. This strategy enables us to
identify key markers in one analytical run on which
ﬁnally a classiﬁcation model of minimized error rate is
built. We used forward selection with a backtracking
facility. Search termination, i.e., the amount of back-
tracking, was set to 5. LRA was chosen since class mem-
bership is assigned by a probability measure. This
measure is of importance if prognostic and diagnosticquestions in a clinical context arise. The probability
for class membership is given as P (Y = 1) = 1/[1 +
exp(z)], where z represents the logit of the model. Basi-
cally, LRA was designed for a two-class problem. For
multiple hypotheses testing, the classiﬁcation problem
can be reduced to a two-class problem by testing all pos-
sible pair-wise combinations or by using a multinomial
logistic regression approach.
For the train and validation cycle we used leave-one
out cross validation of the overall data analysis process
to avoid underestimation of error rates due to the
small number of cases per class. Generally, train and
test or stratiﬁed 10-fold cross validation is suggested
if the datasets are larger. The models classiﬁcation
accuracy was assessed by determining the established
quality measures: accuracy, recall (TP rate), and preci-
sion [29].
2.6.2. Cluster analysis
Hierarchical cluster analysis was applied to divide
MFS phenotypes into meaningful subgroups. It permits
the user to interactively change a given cluster hierarchy
with visual feedback [30]. We used the complete linkage
approach, i.e., D (Cn,Ck) = Max[D (Ci,Ck),D (Cj,Ck)],
to calculate the distances. No attribute-wise normali-
zation was required because of the dichotomous charac-
ter of phenotypic data (symptom present/absent),
and Manhattan distance was chosen as the distance
function. To determine a proper number of clusters,
the linkage distance (scaled between 0 and 1) must be
changed.
For assessment of cluster results we evaluated the
proportions of the diﬀerent mutation classes and deter-
mined the frequency of manifestations in each cluster.
Additionally, we calculated the entropy H of each clus-
ter according to Eq. (2) to estimate the homogeneity/in-
homogeneity of manifestations in the cluster.3. Results
3.1. Frequency and scoring matrices
Mutation classes were speciﬁed at diﬀerent levels of
mutational information. Scoring matrices were generat-
ed based on data subsets returned from DB queries uti-
lizing the underlying data model. Table 2 summarizes
the frequencies of investigated symptoms w.r.t. speciﬁed
classes. Table 3 shows the corresponding score sets.
By way of example, three classes of mutations, i.e.,
Sub/Mis, Sub/Stop, and Del/Fs, could be speciﬁed at
the level of type and consequence of mutations. Within
these classes, ectopia lentis (EL)manifested in 82%ofmis-
sense mutations (score 89), but only in 22% of nonsense
mutations (score35). Interestingly, in deletions causing
FS + PTCweobserved a similarly decreased frequency of
Table 3
Score matrices M and classiﬁcation accuracy of matching
Matrix Mutation class EL AADIL AADIS MVP PC PES ASR WTS SC PE JH HAP SA HE sc Rec. Prec. Acc.
M1 Substitutions 46 14 1 21 7 3 18 16 7 6 19 9 27 0 194 67.2 80.8 65.0
Non-substitutions 29 16 1 28 8 5 25 19 8 5 22 10 39 0 215 59.1 40
M2 Sub/Mis 89 16 7 17 10 1 22 15 9 16 23 20 29 9 284 82.1 79 64.7
Sub/Stop 35 18 30 29 47 2 27 27 32 9 24 40 40 3 362 18.5 50
Del/Fs 31 46 6 31 14 2 25 42 1 7 15 23 41 6 291 61.3 42.2
M3 Sub/Mis/e1–e23 79 9 6 19 16 2 24 21 21 1 39 27 18 6 288 66.7 32.8 34.6
Sub/Mis/e24–e68 37 14 1 7 1 3 8 3 7 22 7 2 24 17 154 14.6 41.2
M4 Sub/Mis/Transition 60 18 5 15 15 9 20 18 10 13 16 18 24 27 268 0.04 100 38.5
Sub/Mis/Transversion 48 1 5 9 8 0 11 1 2 8 19 8 18 11 148 100 36.8
M5 507del1; Y170TfsX20 31 50 0 89 111 0 75 68 0 0 31 64 82 0 601 — — —
7801C > T; Q2601X 26 49 0 87 86 0 116 67 0 7 41 63 81 0 621 — — —
Score matricesM1–M5 correspond to the diﬀerent levels of mutational information as shown in Table 2 (e.g.,M1 = Type (DNA)). Score values are dimensionless. sc is the accumulated absolute score
w.r.t. a mutation class. Classiﬁcation accuracy (Rec. = recall, Prec. = precision, and Acc. = accuracy) is given in %. Balanced matrices ðM1–M4Þ are not explicitly shown.
Table 2
Frequencies of clinical symptoms at diﬀerent levels of mutational information
Information level Mutation class EL AADIL AADIS MVP PC PES ASR WTS SC PE JH HAP SA HE n Age
Database All entries 60 72 11 56 35 5 46 64 51 21 76 66 58 20 163 24(15)
Type (DNA) Substitutions 66 69 11 51 34 4 42 61 50 22 72 64 52 20 119 24(16)
Non-substitutions 41 80 11 68 39 7 57 73 55 18 86 70 75 20 44 26(15)
Type (DNA) and consequence (Prot) Sub/Mis 82 65 8 49 31 5 36 58 47 26 67 58 45 23 78 23(15)
Sub/Stop 22 81 22 70 56 4 59 78 67 15 89 85 78 19 27 30(15)
Del/Fs 35 94 6 71 42 3 58 84 52 16 84 77 77 16 31 27(16)
Type, consequence and location/event Sub/Mis/e1–e23 93 67 3 43 23 3 27 50 37 20 47 47 47 17 30 28(16)
Sub/Mis/e24-e68 75 65 10 52 35 6 42 63 54 29 79 65 44 27 48 20(14)
Sub/Mis/Transition 82 62 8 48 26 8 34 54 46 26 68 56 44 30 50 25(17)
Sub/Mis/Transversion 82 71 7 50 39 0 39 64 50 25 64 61 46 11 28 19(11)
Explicit mutation 507del1; Y170TfsX20 17 100 0 100 83 0 83 100 0 0 50 100 100 0 6 20(12)
7801C > T; Q2601X 75 100 0 100 75 0 100 100 0 25 100 100 100 0 4 23(13)
Frequencies of symptoms are given in %. For abbreviations of manifestations see text. Non-substitutions are represented by Del, Ins, Dup, and Indel mutations. Age is given as mean (SD) years. e is
exon; n is number of tuples per mutation class.
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the second highest proportion of aortic dilatation (AA-
DIL = 81%, score = 18) and the highest risks for aortic
dissection (AADIS = 22%, score = 30), and thus lead to
the most severe phenotypic expressions in the CVS with
high risk of life-threatening complications. The highest
accumulated absolute score sc was also calculated for this
mutation class (362), which emphasizes its low degree of
phenotypic similarity w.r.t. DB. Explicit mutations, how-
ever, yielded the largest sc values (s507del1 = 601,
s7801C>T = 621) arising from maximum homogeneity of
several manifestations. Moreover, both mutations point
out a close phenotypic similarity since phenotypic expres-
sions are almost equal.
3.2. Assignment of MFS phenotypes to speciﬁed mutation
classes
Four sc-balanced matrices, M1–M

4, were generated.
For each matrix M*, similarity requests w.r.t. the speci-
ﬁed mutation classes c 2 M* were performed by testing
data of our research DB. Cases which could not be as-
signed to one of the classes c speciﬁed in M* prior to
these experiments were excluded because they were
undeﬁned in M*. Classiﬁcation accuracy of matching
is summarized in Table 3.
Similarity requests w.r.t. score matrixM1 lead to a re-
call rate of 67% (substitutions) vs. 59% (non-substitu-
tions), with an overall classiﬁcation accuracy of 65%.
Despite the lowest level of mutational information, re-
call rates were remarkably high so that if all Gent crite-
ria were considered we would even expect a higherTable 4
Similarity request for mutation 507del1;Y170TfsX20 on DB (best 20 hits)
No. Nucleotide changes AA changes Type/consequence
1 7801 C > T Q2601X Sub/Stop
2 7801 C > T Q2601X Sub/Stop
3 2581 C > T R861X Sub/Stop
4 6423 del1 L2104fsX? Del/Fs
5 507 del1 Y170fsX20 Del/Fs
6 507 del1 Y170fsX20 Del/Fs
7 7801 C > T Q2601X Sub/Stop
8 4567 C > T R1521X Sub/Stop
9 507 del1 Y170fsX20 Del/Fs
10 507 del1 Y170fsX20 Del/Fs
11 5065 + 3_5065 + 7del5 ? Del-Splice/?
12 461 G > C C154S Sub/Mis
13 6661 T > C C2221R Sub/Mis
14 507 del1 Y170fsX20 Del/Fs
15 8080 C > T R2694X Sub/Stop
16 5826 C > A C1942X Sub/Stop
17 5826 C > A C1942X Sub/Stop
18 3302 A > G Y1101C Sub/Mis
19 3464 del17 R1192fsX? Del/Fs
20 1206 del1 P404fsX44 Del/Fs
? denotes data not available (length of frameshift, AA change or consequenaccuracy. Three mutation classes (missense, nonsense
mutations, and deletions causing FS + PTC) could be
generated at the level of type and consequence ðM2Þ.
Eighty-two percent of Sub/Mis mutations and 61% of
Del/Fs were correctly assigned, while the majority of
nonsense mutations were wrongly classiﬁed to the Del/
Fs class. Comparing score sets of Sub/Stop and Del/
Fs, both groups yielded partly similar score values,
which cause the incorrect assignment. Location and type
of mutational events were considered for class speciﬁca-
tion in M3 and M

4. Recall values of 0.04% and 14.6%,
respectively, demonstrated that one of both classes was
wrongly assigned. Marginal diﬀerences between the phe-
notypic expressions emphasize this result.
3.3. Requests of explicit mutations on DB
Similarity requests of explicit mutations on DB are
applicable if requested mutations can be characterized
by a score set. We performed a request for the mutation
507del1;Y170TfsX20 of which a score set was generable
(see Table 3, M5). The returned query result is shown in
Table 4.
The best 20 hits (12% of DB) assessed by the simi-
larity measure sˆm are displayed. Eighty percent of them
are Sub/Stop or Del/Fs mutations, one is a deletion-
splice site mutation (Del-Splice/?), and 15% are Sub/
Mis mutations. No substitution-splice site mutations
were returned. Among the ﬁrst 10 hits solely Sub/Stop
or Del/Fs mutations were displayed. The 507del1 muta-
tion on which the query score set was generated was dis-
played four times.Exon/intron Domain Age (y) sˆm Rank
62 cb-EGF 45 43 213 1
62 cb-EGF 45 16 213 1
21 hybrid 49 213 1
52 LTBP 6 45 213 1
5 EGF 3 43 211 2
5 EGF 3 14 211 2
62 cb-EGF 45 18 211 2
36 cb-EGF 26 49 211 2
5 EGF 3 10 208 3
5 EGF 3 18 208 3
IVS40 Intronic 16 207 4
5 EGF 3 14 202 5
54 cb-EGF 38 27 200 6
5 EGF 3 20 197 7
64 C-term 22 197 7
47 cb-EGF 33 18 197 7
47 cb-EGF 33 22 197 7
26 cb-EGF 16 17 197 7
28 cb-EGF 18 6 197 7
10 Pro-rich 7 195 8
ce at the protein level).
Fig. 2. Hierarchical cluster analysis of MFS clinical manifestations. Left of the mosaic the type and consequence of mutations are shown. The
hierarchical tree is depicted to the right of the mosaic. The clustered manifestations are given at the top; the scale measure of the linkage distance is
shown on the bottom. Sub/Mis = missense mutation, Sub/Stop = nonsense mutation, Del/Fs = deletion/FS + PTC.
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We focused on the investigation of the Sub/Mis, Sub/
Stop, and Del/Fs mutation classes. Here, key manifesta-
tions could be identiﬁed on which LRA models of min-
imal classiﬁcation error rates were built.
Superior classiﬁcation accuracy was achieved when
separating missense mutations from stop and/or dele-
tions/FS + PTC mutations (both models 80%). Highest
discriminatory performance yielded the Sub/Mis vs.
Sub/Stop model (accuracy = 87%), however, with
unbalanced recall rates of 92% (Sub/Mis) and 70%
(Sub/Stop), respectively. Ectopia lentis (EL) represents
the hallmark manifestation in all three classes. In addi-
tion to EL ascending aortic dilatation (AADIL) and
one skeletal major symptom (WTS) distinguished be-
tween Sub/Mis and Sub/Stop mutations, ascending
aortic dissection (AADIS) and several skeletal manifes-
tations (PC, ASR, WTS, PE, and JH) distinguished be-
tween Sub/Mis and Del/Fs mutations, and thus were
identiﬁed as the predominant diagnostic markers.
Merging Sub/Stop and Del/Fs class, and testing it
against the Sub/Mis class, EL, PC, ASR, PE, and
HAP were the discriminatory markers. EL, AADIL
and AADIS were the markers discriminating between
Sub/Stop and Del/Fs mutations best. However, classi-
ﬁcation accuracy of the latter model was relatively
low (64%, recall 87% and 37%). Mitral valve prolapse
(MVP) and both skin minor criteria (HE, SA) never
appeared in the selected subsets and do not seem to
have diagnostic value when distinguishing between
Sub/Mis, Sub/Stop, and Del/Fs mutations.
3.5. Cluster analysis
Hierarchical cluster analysis was performed on the set
of clinical manifestations. Again, we focused on sub-
jects carrying a Sub/Mis, Sub/Stop or Del/Fs mutation
(Fig. 2). Table 5 summarizes the evaluation of identiﬁed
clusters.
Four meaningful clusters were generated at a linkage
distance >0.2. Here, clusters c1–c3, merged at the linkage
distance <0.2 were more closely related to each other
than to the remaining cluster c4. Cluster c4 diﬀered sig-
niﬁcantly from c1 to c3, showing the mildest phenotypic
expressions. Here, 11 of 14 symptoms showed a frequen-
cy below 50%, nine indicated a frequency even below
25%. Ninety-two percent of this cluster consisted of mis-
sense mutations. The mean probability that P (Sub/
Mis = 1) ranged between 81 and 93%, however depend-
ed on the applied LRA model. The most severe pheno-
type was represented by cluster c10 , one of four sub-
clusters of c1 split up at a linkage distance >0.45, and
contained predominantly Sub/Stop and Del/Fs muta-
tions (together 87% vs. 13% Sub/Mis). In parallel, the
mean probability P (Sub/Mis = 1) decreased to 61–78%
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cluster c10 achieved the lowest value (2.57 bit vs. 5.24 bit
for c4) which can be explained by maximal class homo-
geneity of ﬁve symptoms (AADIL, MVP, WTS, HAP,
and SA > 95%) and additionally the absence of three
manifestations (AADIS, PES, and HE). Thus, cluster
c10 is closely correlated with Sub/Stop and Del/Fs muta-
tions, and c4 with Sub/Mis mutations.4. Discussion
Genotype–phenotype correlation in humans with
FBN1 gene mutations is a challenging bioinformatics
task. In particular, the age-related and pleiotropic nat-
ure of the MFS as well as its intra- and inter-familial
heterogeneity seem to make this task unmanageable
[10,17,19]. The lack of a publicly available FBN1 re-
source providing a maximum degree of genetic and phe-
notypic information, and the absence of an informatics
framework for data management, analysis, and repre-
sentation are mainly responsible for the moderate pro-
gress of deﬁning genotype–phenotype correlation.
Indeed, the two public FBN1 mutation DBs, HGMD
(Human gene mutation database, http://archive.uwcm.
ac.uk/uwcm/mg/search/127115.html) and UMD (Uni-
versal mutation database, www.umd.be:2030/gene.html
and www.umd.necker.fr), are not suﬃcient to systemati-
cally link genetic and clinical information; while HGMD
focuses on the collection, description, and literature anno-
tation of published FBN1 mutations, UMD includes
some more phenotypic information. UMD is currently
the only publicly available FBN1 genotype–phenotype
database that provides data at DNA, protein, and clinical
levels similar to our resource [4]. The clinical information,
however, contains merely the involvement (+/) of the
aﬀected organ systems, and therefore UMD is useless
for extended genotype–phenotype investigations.
In this article, we propose a bioinformatics frame-
work for FBN1 genotype–phenotype correlation, which
will be publicly available via a web portal. A central
component of the information system is a relational
DBMS for storing and managing mutation data, clinical
data according to the Gent nosology and, in future,
additional aortic elastic parameters to better monitor
aortic abnormality [9,10]. The underlying database
scheme represents a biological model of a multi-systemic
inherited disease, which describes mutations and their
polymorphisms in DNA and protein sequences, and
the diseases variability in phenotypic expression com-
prehensively. Thus, our methodology is well generaliz-
able to other monogenic diseases causing phenotypic
pleiotropy; only an adaptation of the phenotype data
model is needed. Depending on the amount of muta-
tions, the number of involved organ systems and diag-
nostic key features, and the number of required casesto perform genotype–phenotype correlations vary. If
data analysis is performed at mutation type and conse-
quence (cDNA and protein) level, a number of cases
comparable to our study is essential. Considerably more
data are required, if data are analyzed at the level of
location of mutational events in the gene or the aﬀected
protein domains, so that the web portal will help to col-
lect suﬃcient data worldwide to perform genotype–phe-
notype investigations at this level in future.
For advanced DB requests the proposed data model
permits queries for the wide spectrum of mutation types,
subtypes and their mutational events which are required
for the generation of the score sets at diﬀerent levels. We
introduced log-likelihood weights as similarity measures
to match phenotypes, similar to the well-known PAM or
BLOSUM matrices, which were developed for protein
sequence alignment. Thus this simple retrieval technique
permits the search of mutations of related phenotypes
on DB, as exempliﬁed for 507del1;Y170TfsX20, which
may be helpful, e.g., to estimate the degree of intra-
and inter-familial heterogeneity of the syndrome.
Relevant diagnostic markers were identiﬁed using a
wrapper-based feature selection approach. This strategy
is preferred to the ﬁlter method, since computational
limitations caused by the size of DB (>600 published
FBN1 mutations) and the dimensionality of investigated
data (n < 30) may not arise [26,27]. In particular, LRA
models fulﬁll the requirement of clinical experts to have
a quantitative (probability), not only a qualitative mea-
sure for patient classiﬁcation. Hierarchical cluster anal-
ysis was proposed for sub-grouping phenotype data.
Due to the high variability within the MFS phenotype,
mutation classes of enhanced phenotypic homogeneity
are surprising (cf. c10 and c4), since clusters with high
class homogeneity are indicators for a very close geno-
type–phenotype relationship. The proposed data mining
strategy, which takes both a supervised and non-super-
vised view of data analysis into account, properly
addresses prognostic and diagnostic questions for the
correlation task. Nevertheless, the evaluation and fur-
ther development of data mining procedures are in pro-
gress, so that in the future new meaningful approaches
can readily be incorporated in the framework.
A few accepted genotype–phenotype correlations in
the MFS have been reported, e.g., with a hot spot for
neonatal MFS in exons 24–32 or a clustering of muta-
tions causing milder forms in exons 59–65. More com-
mon occurrence of large-joint hypermobility (JH), less
common ectopia lentis (EL), and retinal detachment
are associated with premature termination codon
(PTC) mutations, while, e.g., missense mutations show
a high frequency of EL [1,13–17,31]. Using the proposed
bioinformatics framework, some of the aforementioned
correlations could be conﬁrmed. A few novel ones were
identiﬁed, although some limitations concerning the
incomplete description of symptoms in the literature
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Maximum phenotypic dissimilarity was found between
missense mutations and the groups of nonsense muta-
tions and deletions causing FS + PTC. The latter both
classes indicate similar phenotypic expressions (cf. Ta-
bles 2 and 3). This can be explained by related mutation-
al events causing termination of ﬁbrillin-1 synthesis. Key
manifestations, which are relevant for best discriminat-
ing between Sub/Mis and Sub/Stop + Del/Fs classes,
are EL and several skeletal (major and minor) criteria,
but not manifestations of the CVS and the skin system.
Comparing missense and nonsense mutations—indepen-
dent of the location of the mutational event—AADIS
appears to be an additional key marker predominantly
observed in patients carrying a nonsense mutation.
More severe manifestations in the CVS lead to a higher
risk of life-threatening aortic dissection or rupture which
require immediate therapeutic intervention. The most
severe phenotypic expressions were solely found in pa-
tients carrying a Sub/Stop or Del/Fs mutation, while
the mildest MFS phenotype appeared in Sub/Mis muta-
tions. No diﬀerence was found if, e.g., point mutations
at diﬀerent gene locations (exons 1–24 vs. exons 25–
68) or with diﬀerent mutational events (transitions vs.
transversions) were compared.
In summary, our proposed bioinformatics framework
for FBN1 genotype–phenotype correlation provides a
pipeline for data management and analysis which can
help to better link genetic and clinical information.
Using this framework some well-known genotype–phe-
notype correlations could be conﬁrmed and other novel
correlations were identiﬁed, which emphasize the power
of the methodology to address these important ques-
tions with respect to diagnosis and therapy of MFS.Acknowledgments
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